Health Care & Life Sciences » Biotechnology | BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.
Stock Exchange Other OTC
EPS
$0.03
Market Cap
$10.36 M
Shares Outstanding
157.83 M
Public Float
34.7 M
BriaCell Therapeutics Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
157.83 M
Public Float
-
BriaCell Therapeutics Corp.
Stock Exchange Toronto Ventures Stock Exchange
EPS
CAD0.04
Market Cap
CAD12.75 M
Shares Outstanding
62.02 M
Public Float
16.28 M

Profile

Address
Bellevue Centre
West Vancouver British Columbia V7T 2X1
Canada
Employees -
Website http://www.briacell.com
Updated 07/08/2019
BriaCell Therapeutics Corp. operates as an immuno-oncology company which engages in the development of immunotherapy treatments for cancer. Its product candidate, BriaVax, is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. It is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.

Financials

View All

William V. Williams
President, Chief Executive Officer & Director
Charles L. Wiseman
Director